Abstract: TH-OR088
Extended In-Center Nocturnal vs. Conventional Daytime Dialysis: The NightLife Trial
Session Information
- Late-Breaking Research Orals - 1
November 06, 2025 | Location: Grand Ballroom C, Convention Center
Abstract Time: 05:18 PM - 05:30 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Burton, James, University of Leicester, Leicester, England, United Kingdom
- Hull, Katherine Leigh, University of Leicester, Leicester, England, United Kingdom
- Quann, Niamh, University of Leicester, Leicester, England, United Kingdom
- Waheed, Ghazala, University of Leicester, Leicester, England, United Kingdom
- Gray, Laura Jayne, University of Leicester, Leicester, England, United Kingdom
Group or Team Name
- The NightLife Investigators.
Background
There are increasing observational data demonstrating benefits of in-centre nocturnal hemodialysis (INHD) on health-related outcomes. The multicentre, pragmatic NightLife Trial (ISRCTN 87042063) aimed to test the impact of INHD versus conventional hemodialysis (CHD) on quality of life.
Methods
Prevalent adult HD patients were randomly assigned to receive either 6-months INHD (6-8 hrs) or CHD (3.5-5 hrs; see figure). The primary outcome was Kidney Disease Quality of Life-36 (KDQoL-36) total score between groups over 6-months. Secondary outcome measures presented included intervention adherence, a comparison of KDQoL-36 domain scores between baseline and 6-months, and measures of safety. The trial was stopped early by the funder due to site set-up challenges.
Results
Groups were well matched (100 randomised, 57 INHD, see figure). The INHD group averaged 6.61 hrs/session vs 4.07 hrs/session in the CHD group. INHD had no effect on KDQoL-36 total score over 6-months with an adjusted mean difference between groups of 3.00 (-12.4 to 18.3). The comparison of KDQoL-36 domain scores is shown in the table. Only 2 participants withdrew due to the intervention (see figure). No serious adverse events (SAEs) related to INHD were reported.
Conclusion
Compared to CHD, INHD was not associated with improvements in total KDQoL-36 score over 6-months, however the study was underpowered. In a population with high symptom burden, observed differences in the KDQoL-36 kidney disease component summary score needs further investigation. With no associated SAEs, and good patient adherence to the intervention, INHD may offer an opportunity to increase dialysis capacity whilst also increasing patient choice.
Figure: CONSORT diagram
Table: KDQoL domain scores at baseline and 6-months
Funding
- Government Support - Non-U.S.